Pfizer, the biopharmaceutical company, said a trial of a new generic vaccine appeared to show some promising results,media BGR reported. Trials have reportedly shown that the vaccine causes the body to produce antibodies in a similar way to human infection. Double-blind trials will continue, but one should not expect easy access to vaccines until 2021.
David Rach was one of the first to be tested for the COVID-19 vaccine. The trial was carried out by scientists at the University of Maryland School of Medicine, who have been observing Rach’s condition in the hope that the vaccine will use antibodies to boost his body’s immune system and pre-emptively fight the virus. Now, Pfizer, which developed the vaccine, says it appears to be effective, at least for now.
In a recent update with Pfizer, the company said the vaccine produced antibodies in volunteers similar to those actually infected with the coronavirus, Rach told WJLA.
“From a participant’s point of view and a graduate student studying immunology, it’s exciting because it’s expected to get a vaccine by next year and life is returning to normal,” Rach said. “When Pfizer made an announcement, I found out, and my friends started saying hello to me on Facebook, ‘Oh, your picture’s on the news again!'” I just thought, wait, what’s going on? Seeing it really had an effect, the vaccine produced antibodies, and there was a release of the ingredients. “
It is important to note that although Rach was the first participant, he was not the only one involved in the trial, and because the structure of the trial was double-blind, Rach did not know whether he had been vaccinated or placed. Still, Pfizer says the trial itself is showing results, so if Rach receives the vaccine, he may be one of the first people in the world to be immune to COVID-19 without first infection, depending on his response to the second dose.